64798-33-0

Usage

Type of compound

Nitrile

Key structural feature

Contains a cyano group attached to a carbon atom

Characteristic substituent

3-chloro-phenyl group attached to the second carbon atom

Usage

Synthesis of pharmaceuticals and agrochemicals, potential building block in organic synthesis, potential applications in medicinal chemistry

Potential

Structural features and biological activities

Upstream product

• 74-83-9 methyl bromide 
• 1529-41-5 3-chloro-benzeneacetonitrile 
• 74-88-4 methyl iodide 
• 766-84-7 3-chloro-benzonitrile 

Downstream Products

• 64798-34-1 2-(3-chloro-phenyl)-2-methyl-propionic acid amide 
• 92015-24-2 2-(3-chlorophenyl)-2-methylpropan-1-amine 
• 1035261-92-7 diethyl 2-(2-(3-chlorophenyl)-2-methylpropanoyl)malonate 
• 64798-36-3 2-(3-chloro-phenyl)-2-methyl-propionyl chloride 
• 1440519-53-8 [2-(3-chlorophenyl)-2-methylpropyl]carbamic acid methyl ester 
• 1239963-98-4 2-chloro-4-(2-(1-(4-fluoro-3-methoxyphenyl)-2-mercapto-1H-imidazol-5-yl)propan-2-yl)benzenesulfonamide 
• 1239964-05-6 2-chloro-4-(4-(3-(4-fluoro-3-methoxyphenyl)thioureido)-2-methyl-3-oxobutan-2-yl)benzenesulfonamide 
• 1239964-04-5 4-(4-amino-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide hydrochloride 
• 1239964-03-4 4-(4-azido-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide 
• 1239964-02-3 4-(4-bromo-2-methyl-3-oxobutan-2-yl)-2-chlorobenzenesulfonamide 
• 1239964-01-2 2-chloro-4-(2-methyl-3-oxobutan-2-yl)benzenesulfonamide 
• 1239964-00-1 2-chloro-4-(2-methyl-3-oxobutan-2-yl)benzene-1-sulfonyl chloride 
• 1017478-92-0 3-(3-chlorophenyl)-3-methylbutan-2-one 
• 1239963-99-5 3-(3-chlorophenyl)-3-methylbutan-2-ol 

Relevant academic research and scientific papers

BENZAMIDE COMPOUNDS AS ROR GAMMA MODULATORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, R1, R2, R3, R4, R5, n and p are as defined herein, which are active as modulators of retinoid-related orphan receptor gamma t (RORγt). These compounds prevent, inhibit, or suppress the action of RORγt and are therefore useful in the treatment of RORγt mediated diseases, disorders, syndromes or conditions such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

Structure-activity relationship of N,N′-disubstituted pyrimidinetriones as CaV1.3 calcium channel-selective antagonists for Parkinson's disease

CaV1.3 L-type calcium channels (LTCCs) have been a potential target for Parkinson's disease since calcium ion influx through the channel was implicated in the generation of mitochondrial oxidative stress, causing cell death in the dopaminergic neurons. Selective inhibition of CaV1.3 over other LTCC isoforms, especially CaV1.2, is critical to minimize potential side effects. We recently identified pyrimidinetriones (PYTs) as a CaV1.3-selective scaffold; here we report the structure-activity relationship of PYTs with both CaV1.3 and CaV1.2 LTCCs. By variation of the substituents on the cyclopentyl and arylalkyl groups of PYT, SAR studies allowed characterization of the CaV1.3 and Ca V1.2 LTCCs binding sites. The SAR also identified four important moieties that either retain selectivity or enhance binding affinity. Our study represents a significant enhancement of the SAR of PYTs at CaV1.3 and CaV1.2 LTCCs and highlights several advances in the lead optimization and diversification of this family of compounds for drug development.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

NAPHTHALENONE COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS, AND USES THEREOF

Compounds of Formula (I) and Formula (II) are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula(I) and Formula (II) have the following structures, where the definitions of the variables are provided herein.

3-(α,α-Dimethylbenzyl)urea compounds, compositions, and their use as herbicides

A compound of the general formula (I): STR1 wherein X is halogen or trifluoromethyl, n and m are 0 or 1, R1 is lower C1 - C2 alkyl or C1 - C2 alkoxy and R2 is C4 - C5